Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease

Nutrition

Volumn 25, Issue 2, 2009, Pages 172-181

  Valentini, Luzia ^a   Wirth, Eva Katrin ^a   Schweizer, Ulrich ^a   Hengstermann, Susanne ^a   Schaper, Lennart ^a   Koernicke, Thomas ^a   Dietz, Ekkehart ^a   Norman, Kristina ^a   Buning, Carsten ^a   Winklhofer Roob, Brigitte M ^b   Lochs, Herbert ^a   Ockenga, Johann ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adaptive mechanisms; Adiponectin; Crohn's disease; Leptin; Pathophysiology; Resistin; Retinol binding protein 4; Ulcerative colitis; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL BINDING PROTEIN 4;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENTERITIS; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PRIORITY JOURNAL; RELAPSE; REMISSION; ULCERATIVE COLITIS;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; HYPERINSULINISM; INFLAMMATION MEDIATORS; LEPTIN; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL-BINDING PROTEINS; YOUNG ADULT;

EID: 58149472945     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2008.07.020     Document Type: Article

References (45)

1. Tilg H., and Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 (2006) 772-783
2. Fain J.N. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74 (2006) 443-477
3. John B.J., Irukulla S., Abulafi A.M., Kumar D., and Mendall M.A. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther 23 (2006) 1511-1523
4. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 (2004) 447-452
5. Pang S.S., and Le Y.Y. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol 3 (2006) 29-34
6. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 7121 (2006) 860-867
7. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 580 (2006) 2917-2921
8. Kralisch S., Sommer G., Deckert C.M., Linke A., Bluher M., Stumvoll M., et al. Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol 32 (2007) 161-171
9. Sweeney L.L., Brennan A.M., and Mantzoros C.S. The role of adipokines in relation to HIV lipodystrophy. AIDS 21 (2007) 895-904
10. Toussirot E., Streit G., and Wendling D. The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr Med Chem 14 (2007) 1095-1100
11. Taskapan M.C., Taskapan H., Sahin I., Keskin L., Atmaca H., and Ozyalin F. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality. Ren Fail 29 (2007) 147-154
12. Ockenga J., Bischoff S.C., Tillmann H.L., Rifai K., Widjaja A., Boker K.H., et al. Elevated bound leptin correlates with energy expenditure in cirrhotics. Gastroenterology 119 (2000) 1656-1662
13. Ockenga J., Tietge U.J., Boker K.H., Manns M.P., Brabant G., and Bahr M.J. Distinct roles of free leptin, bound leptin and soluble leptin receptor during the metabolic-inflammatory response in patients with liver cirrhosis. Aliment Pharmacol Ther 25 (2007) 1301-1309
14. Desreumaux P., Ernst O., Geboes K., Gambiez L., Berrebi D., Muller-Alouf H., et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 117 (1999) 73-81
15. Valentini L., Buning C., Hengstermann S., Schaper L., Koernicke T., Norman K., et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition 24 (2008) 694-702
16. Ahualli J. The fat halo sign. Radiology 242 (2007) 945-946
17. Peyrin-Biroulet L., Chamaillard M., Gonzalez F., Beclin E., Decourcelle C., Antunes L., et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. Gut 56 (2007) 577-583
18. Schaffler A., and Herfarth H. Creeping fat in Crohn's disease: travelling in a creeper lane of research?. Gut 54 (2005) 742-744
19. Best W.R., Becktel J.M., Singleton J.W., and Kern Jr. F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
20. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
21. Harvey R.F., and Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1 8167 (1980) 514
22. Sattler W., Puhl H., Hayn M., Kostner G.M., and Esterbauer H. Determination of fatty acids in the main lipoprotein classes by capillary gas chromatography: BF3/methanol transesterification of lyophilized samples instead of Folch extraction gives higher yields. Anal Biochem 198 (1991) 184-190
23. Pirlich M., Schutz T., Spachos T., Ertl S., Weiss M.L., Lochs H., et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 32 (2000) 1208-1215
24. Lautz H.U., Selberg O., Korber J., Burger M., and Muller M.J. Protein-calorie malnutrition in liver cirrhosis. Clin Investig 70 (1992) 478-486
25. Kushner R.F., and Schoeller D.A. Estimation of total body water by bioelectrical impedance analysis. Am J Clin Nutr 44 (1986) 417-424
26. Sitaraman S., Liu X., Charrier L., Gu L.H., Ziegler T.R., Gewirtz A., et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J 18 (2004) 696-698
27. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Voudouri T., and Kouroumalis E.A. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 12 (2006) 100-105
28. Nishi Y., Isomoto H., Ueno H., Ohnita K., Wen C.Y., Takeshima F., et al. Plasma leptin and ghrelin concentrations in patients with Crohn's disease. World J Gastroenterol 11 (2005) 7314-7317
29. Paul G., Schaffler A., Neumeier M., Furst A., Bataillle F., Buechler C., et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 12 (2006) 471-477
30. Yamamoto K., Kiyohara T., Murayama Y., Kihara S., Okamoto Y., Funahashi T., et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 54 (2005) 789-796
31. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178 (2007) 1748-1758
32. Kloting N., Graham T.E., Berndt J., Kralisch S., Kovacs P., Wason C.J., et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 6 (2007) 79-87
33. Muoio D.M., and Newgard C.B. Metabolism: A is for adipokine. Nature 436 7049 (2005) 337-338
34. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
35. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
36. Bregenzer N., Hartmann A., Strauch U., Scholmerich J., Andus T., and Bollheimer L.C. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis 12 (2006) 53-56
37. Bendet N., Scapa E., Cohen O., Bloch O., Aharoni D., Ramot Y., et al. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection. Scand J Gastroenterol 39 (2004) 650-656
38. Angelini G., Cavallini G., Bovo P., Brocco G., Castagnini A., Lavarini E., et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol 3 (1988) 185-193
39. Katznelson L., Fairfield W.P., Zeizafoun N., Sands B.E., Peppercorn M.A., Rosenthal D.I., et al. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab 88 (2003) 5468-5472
40. Capristo E., Mingrone G., Addolorato G., Greco A.V., and Gasbarrini G. Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease. Aliment Pharmacol Ther 13 (1999) 209-217
41. Heslin M.J., Newman E., Wolf R.F., Pisters P.W., and Brennan M.F. Effect of hyperinsulinemia on whole body and skeletal muscle leucine carbon kinetics in humans. Am J Physiol Endocrinol Metab 262 pt 1 (1992) E911-E918
42. Dandona P., Chaudhuri A., Mohanty P., and Ghanim H. Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 10 (2007) 511-517
43. Langhorst J., Eisenbruch S., Koelzer J., Rueffer A., Michalsen A., and Dobos G.J. Noninviasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin, and OMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103 (2008) 162-169
44. Nordberg E., Schaufelberger C., and Bosaeus I. The effect of glucocorticoids on fat and lean tissue masses in giant cell arteritis. Scand J Rheumatol 27 (1998) 106-111
45. Lippuner K., Casez J.P., Horber F.F., and Jaeger P. Effects of deflazacort versus prednisolone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metabol 83 (1998) 3795-3802